The company halted its U.S. trial in early September over safety concerns, after a trial participant reported neurological problems. The study resumed earlier this month after FDA concluded that no evidence linked the volunteer’s symptoms to the shot.
Archiv: messenger ribonucleic acid (mRNA) molecule
AstraZeneca shares slip after analyst says vaccine will struggle to get green light in US – live updates
SVB Leerink analyst Geoffrey Porges said the treatment may never gain approval from US regulator the FDA, and said Astra had highlighted results from a “relatively small” number of patients.
Oxford AstraZeneca Covid vaccine: everything we know so far
No mRNA vaccine has ever been approved by regulators, but the Oxford approach has been used in vaccines given safely to thousands of people of all ages for diseases ranging from TB and malaria to Mers (another coronavirus) and Ebola, for which it is now being used in Uganda and the Democratic Republic of the Congo. Oxford opted for the chimp virus because it has the potential to generate a strong immune response and, since it cannot grow in humans, it should be safe.
Two other frontrunner vaccines, from BioNTech (developed with Pfizer) and Moderna (developed with the US National Institute of Allergy and Infectious Diseases), perform well, according to interim results from phase 3 human trials, achieving more than 90% efficacy. These are based on technology that is new to the vaccine field. Both use genetic material called mRNA, or messenger RNA, which tells human cells how to make coronavirus spike proteins.
Wie Impfstoffzulassung in EU funktioniert
„Unser Plan ist es, die Impfstoffe innerhalb von 24 Stunden nach Zulassung an die Impfzentren zu liefern“, sagte Slaoui in einem Interview mit CNN. Er rechne daher damit, dass bereits am 11. oder 12. Dezember mit den Impfungen begonnen werden könne. Voraussetzung ist eine Notfallzulassung des Impfstoffs.
Studienergebnisse von AstraZeneca: Britischer Impfstoff wirkt zu 70 Prozent
Das Ergebnis bleibt zwar hinter den Werten der Präparate von Pfizer/Biontech und Moderna zurück. Wenn man aber zunächst nur eine halbe Dosis verabreiche und erst einen Monat später eine volle, dann erreiche der Impfstoff eine Effektivität von 90 Prozent, lässt AstraZeneca wissen. Er soll zudem deutlich preiswerter sein, sich sehr viel leichter lagern und weltweit transportieren lassen als andere Vakzine.
Huge thanks to Kate Bingham and the Vaccine Taskforce for all their fantastic work in securing 40 million doses of the @pfizer & @BioNTech_Group vaccine and over 300 million doses of other promising vaccine candidates.
Oxford vaccine is not mRNA based its DNA based. This is prolly the best description right now:
This vaccine needs to be kept at below -80 ^C because it uses mRNA. Not suitable for most clinics and GP practices. My money is still on Oxford to produce a more effective and ergonomic one.
Enges Rennen um den Impfstoff
Damit haben Biontech/Pfizer im Rennen um einen durchschlagenden Impferfolg die Nase vorn. Verbunden damit ist auch ein Durchbruch für die spezielle Technologie, die die beiden Partner, aber auch der deutsche Mitbewerber Curevac und der US-Konzern Moderna nutzen: Bei der Impfung auf mRNA-Basis „mit Erbgutschnipseln“ werden Baupläne für Proteine in die menschlichen Zellen eingeschleust, die dann Antigene herstellen – in diesem Fall gegen das Corona-Virus.
German Pfizer vaccine could be ready before Oxford-AstraZeneca injection and be given to Brits before Christmas
Ms Bingham was appointed chair of the UK’s Vaccine Taskforce for Covid-19 in May and reports directly to the Prime Minister on the progress of a coronavirus vaccine, which experts say is key to controlling the pandemic.
The taskforce, which Ms Bingham says was the ‚brainchild of Sir Patrick Vallance‘ — Number 10’s chief scientific adviser, is at the forefront of putting plans in place to get the UK population vaccinated.
Forbidden Op-Ed: The Sputnik Vaccine as a Lifesaving Global Partnership
The use of two vectors is the unique technology, developed by the Gamaleya Center scientists, which differentiates the Russian vaccine from other adenoviral vector-based vaccines under development around the world. Vaccines based on adenoviral vectors also have clear advantages over other technologies such as mRNA vaccines.
Prospective mRNA vaccines, undergoing clinical trials in the United States and other countries, do not use vectors for delivery and represent an RNA molecule with coronavirus protein code wrapped in a lipid membrane. This technology is promising but its side effects, especially an impact on fertility, have not yet been studied in depth. No mRNA vaccine has yet received regulatory approval in the world.
Impfstoff gegen Covid-19: Russlands Gesundheitsminister nennt Frist von Produktion erster Packungen
„Wenn wir zum Beispiel vom RNA-Impfstoff sprechen, der in anderen Ländern produziert wurde, gab es dann Publikationen – diese können Sie finden, wonach ein Teil der Impfstoffe ohne präklinische Forschungen erschienen ist und sofort bei Menschen eingesetzt worden ist, was in unserem Fall ausdrücklich nicht der Fall ist.“
Chancen und Gefahren der Gen-Impfstoffe
(27.07.2020)
Im Gegensatz zu DNA-Impfstoffen werden RNA-Impfstoffe nicht in den Zellkern transportiert. Daher besteht auch nicht die theoretische Gefahr, dass diese in das Erbgut von Körperzellen integriert wird. Theoretisch wäre es möglich, dass andere bereits im Körper vorhandene Viren die Impf-RNA in DNA „umschreiben“, so dass diese sich doch in das Erbgut einer Zelle integrieren und dort Folgeschäden auslösen könnte. Eine solche Umschreibung wird jedoch nicht beobachtet.
Können m-RNA-Impfungen Menschen mutieren lassen?
(13.07.2020)
Gegen Corona werden erstmals RNA-Impfstoffe erprobt. Dabei wollen Mediziner ihren Patienten ein kleines Stückchen Erbinformation spritzen, die in den menschlichen Zellen die Produktion des Antigens von Sars-CoV-2 auslöst. Das Antigen ist praktisch ein Erkennungsmolekül des Virus und zugleich eine Art Schlüssel, mit dem es in die Zelle eindringt. Produziert eine Zelle diese Antigene, zeigt sie diese auch auf der Zellhülle.
U.K. Orders 90 Million Vaccine Doses from Pfizer and Valneva
“It’s the right thing to be doing to be at the absolute front of the queue to make sure we’re in a position to get those vaccines first when they become available,” Education Secretary Gavin Williamson told the BBC during the government’s media round on Monday.
Why the Bill Gates global health empire promises more empire and less public health
Behind a veil of corporate media PR, the Gates Foundation has served as a vehicle for Western capital while exploiting the Global South as a human laboratory. The coronavirus pandemic is likely to intensify this disturbing agenda.
Battle of the Biotech Unicorns: CureVac vs. Moderna
(06.11.2017)
But despite being competitors, the companies’ CEOs seem to have quite a good relationship and consider each other collaborators rather than enemies. Every year, they organize an mRNA conference together that takes turns between Boston and Berlin to bring together all the stakeholders in the field. It was at this year’s edition, in Berlin, that I had the chance to bring them together for an interview regarding the future of mRNA therapies.
Coronavirus: Biotech company ships first batches of vaccine, to be tested on humans: report
The trials will be held at Kaiser Permanente Washington Health Research Institute in Seattle. Testing will involve 45 young, healthy volunteers and it uses Moderna’s mRNA-1273 vaccine.
„Unlike a normal vaccine, RNA vaccines work by introducing an mRNA sequence (the molecule which tells cells what to build) which is coded for a disease-specific antigen, once produced within the body, the antigen is recognized by the immune system, preparing it to fight the real thing,“ according to the University of Cambridge.
CureVac works on mRNA vaccine for coronavirus
Since 2006, the company has been manufacturing mRNA-based vaccines and therapeutics. It is currently looking to boost its manufacturing capacity to supply up to billions of doses during outbreaks.
CureVac chief technology officer Mariola Fotin-Mleczek said: “Nature has invented mechanisms to activate our immune system against infectious diseases. With our unique messenger RNA technology, we mimic nature and give our body the information on how to fight against the virus.
Moderna : Germany tries to halt U.S. interest in firm working on coronavirus vaccine
CureVac in 2015 and 2018 secured financial backing for development projects from its investor the Bill & Melinda Gates Foundation, working on shots to prevent malaria and influenza.
In the field of so-called mRNA therapeutics, CureVac competes with U.S. biotech firm Moderna and German rival BioNTech, which Pfizer has identified as a potential collaboration partner.